Advances in the treatment of bleeding disorders

Journal of Thrombosis and Haemostasis

Volumn 14, Issue 11, 2016, Pages 2095-2106

  Peyvandi, F ^a,b   Garagiola, I ^b   Biguzzi, E ^a  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

disease management; hemophilia; inherited blood coagulation disorders; innovative therapy; von Willebrand disease

Indexed keywords

BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 10 CONCENTRATE; BLOOD CLOTTING FACTOR 11 CONCENTRATE; BLOOD CLOTTING FACTOR 5 CONCENTRATE; BLOOD CLOTTING FACTOR 8 CONCENTRATE; CONCIZUMAB; DESMOPRESSIN; EGAPTIVON PEGOL; EMICIZUMAB; FITUSIRAN; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 9; UNCLASSIFIED DRUG; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 8; FACTOR VIII, VON WILLEBRAND FACTOR DRUG COMBINATION; RECOMBINANT PROTEIN; VON WILLEBRAND FACTOR;

ABSENCE OF SIDE EFFECTS; BLEEDING DISORDER; BLOOD CLOTTING FACTOR 10 DEFICIENCY; BLOOD CLOTTING FACTOR 11 DEFICIENCY; BLOOD CLOTTING FACTOR 13 DEFICIENCY; BLOOD CLOTTING FACTOR 5 DEFICIENCY; BLOOD CLOTTING FACTOR 7 DEFICIENCY; DRUG APPROVAL; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; EXTENDED HALF LIFE; FOOD AND DRUG ADMINISTRATION; HEMOPHILIA A; HEMOPHILIA B; HUMAN; LOW DRUG DOSE; PLASMA HALF LIFE; PRIORITY JOURNAL; PROTHROMBIN DEFICIENCY; REVIEW; SINGLE DRUG DOSE; VON WILLEBRAND DISEASE; ANIMAL; BLOOD CLOTTING; DRUG COMBINATION; HEMATOLOGIC DISEASE; HEMATOLOGY; MALE; MOUSE; PROCEDURES; TREATMENT OUTCOME;

ANIMALS; BLOOD COAGULATION; DRUG COMBINATIONS; FACTOR VIII; FACTOR X; FACTOR X DEFICIENCY; FACTOR XIII DEFICIENCY; HEMATOLOGIC DISEASES; HEMATOLOGY; HEMOPHILIA A; HUMANS; MALE; MICE; RECOMBINANT PROTEINS; TREATMENT OUTCOME; VON WILLEBRAND FACTOR;

EID: 84995451126     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.13491     Document Type: Review

References (77)

1. Schieppati A, Henter J-I, Daina E, Aperia A. Why rare diseases are an important medical and social issue. Lancet 2008; 371: 2039–41.
2. Peyvandi F, Jayandharan G, Chandy M, Srivastava A, Nakaya SM, Johnson MJ, Thompson AR, Goodeve A, Garagiola I, Lavoretano S, Menegatti M, Palla R, Spreafico M, Tagliabue L, Asselta R, Duga S, Mannucci PM. Genetic diagnosis of haemophilia and other inherited bleeding disorders. Haemophilia 2006; 12(Suppl. 3): 82–9.
3. von Lillicrap D. Willebrand disease: advances in pathogenetic understanding, diagnosis, and therapy. Blood 2013; 122: 3735–40.
4. Palla R, Peyvandi F, Shapiro AD. Rare bleeding disorders: diagnosis and treatment. Blood 2015; 125: 2052–61.
5. World Federation of Hemophilia. Report on the Annual Global Survey 2014. Montreal, Canada: World Federation of Hemophilia, 2015.
6. Peyvandi F, Garagiola I. Treatment of hemophilia in the near future. Semin Thromb Hemost 2015; 41: 838–48.
7. Mannucci PM, Tuddenham EG. The hemophilias – from royal genes to gene therapy. N Engl J Med 2001; 344: 1773–9.
8. Rodriguez-Merchan EC. Chronic ankle instability: diagnosis and treatment. Arch Orthop Trauma Surg 2012; 132: 211–19.
9. Mannucci PM, Ruggeri ZM, Pareti FI, Capitanio A. 1-Deamino-8-d-arginine vasopressin: a new pharmacological approach to the management of haemophilia and von Willebrands’ diseases. Lancet 1977; 1: 869–72.
10. Peyvandi F, Garagiola I, Young G. The past and future of haemophilia: diagnosis, treatments, and its complications. Lancet 2016; 388: 187–97.
11. Manco-Johnson MJ, Abshire TC, Shapiro AD, Riske B, Hacker MR, Kilcoyne R, Ingram JD, Manco-Johnson ML, Funk S, Jacobson L, Valentino LA, Hoots WK, Buchanan GR, DiMichele D, Recht M, Brown D, Leissinger C, Bleak S, Cohen A, Mathew P, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357: 535–44.
12. Tang L, Wu R, Sun J, Zhang X, Feng X, Zhang X, Luke KH, Poon MC. Short-term low-dose secondary prophylaxis for severe/moderate haemophilia A children is beneficial to reduce bleed and improve daily activity, but there are obstacle in its execution: a multi-centre pilot study in China. Haemophilia 2013; 19: 27–34.
13. Coyle TE, Reding MT, Lin JC, Michaels LA, Shah A, Powell J. Phase I study of BAY 94-9027, a PEGylated B-domain-deleted recombinant FVIII with an extended half-life, in subjects with hemophilia A. J Thromb Haemost 2014; 12: 488–96.
14. Tiede A, Brand B, Fischer R, Kavakli K, Lentz SR, Matsushita T, Rea C, Knobe K, Viuff D. Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A. J Thromb Haemost 2013; 11: 670–8.
15. Konkle B, Stasyshyn O, Chowdary P, Bevan DH, Mant T, Shima M, Engl W, Dyck-Jones J, Fuerlinger M, Patrone L, Ewenstein B, Abbuehl B. Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A. Blood 2015; 126: 1078–85.
16. Mahlangu J, Powell JS, Ragni MV, Chowdary P, Josephson NC, Pabinger I, Hanabusa H, Gupta N, Kulkarni R, Fogarty P, Perry D, Shapiro A, Pasi KJ, Apte S, Nestorov I, Jiang H, Li S, Neelakantan S, Cristiano LM, Goyal J, et al. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood 2014; 123: 317–25.
17. Schulte S. Innovative coagulation factors: albumin fusion technology and recombinant single-chain factor VIII. Thromb Res 2013; 131S2: S2–6.
18. Mahlangu J, Lepatan LMP, Boggio L, Klamroth R, Djambas Khayat C, Fischer K, Iosava G, Bensen-Kennedy D, Limsakun T, Veldman A, Ledger KST, Pabinger I, on behalf of the Affinity Investigators. rVIII-Single chain pharmacokinetics in adults, adolescents and children. Haemophilia 2016; 22(Suppl. 2): 19–111.
19. Negrier C, Knobe K, Tiede A, Giangrande P, Møss J. Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B. Blood 2011; 118: 2695–701.
20. Powell JS, Pasi KJ, Ragni MV, Ozelo MC, Valentino LA, Mahlangu JN, Josephson NC, Perry D, Manco-Johnson MJ, Apte S, Baker RI, Chan GC, Novitzky N, Wong RS, Krassova S, Allen G, Jiang H, Innes A, Li S, Cristiano LM, et al. Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B. N Engl J Med 2013; 369: 2313–23.
21. Powell JS, Perry D, Baker RI, Shapiro A, Manco-Johnson MJ, Potts J, Robinson B, Mei B, Pierce G. Analysis of clinical target joint bleeding on prophylactic regimens with recombinant Factor IX Fc fusion protein in patients with severe hemophilia B. Abstracts of the WFH 2014 World Congress. Haemophilia 2014; 20(Suppl. s3): 94.
22. Santagostino E, Negrier C, Klamroth R, Tiede A, Pabinger-Fasching I, Voigt C, Jacobs I, Morfini M. Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients. Blood 2012; 120: 2405–11.
23. Martinowitz U, Lissitchkov T, Lubetsky A, Jotov G, Barazani-Brutman T, Voigt C, Jacobs I, Wuerfel T, Santagostino E. Results of a phase I/II open-label, safety and efficacy trial of coagulation factor IX (recombinant), albumin fusion protein in haemophilia B patients. Haemophilia 2015; 21: 784–90.
24. Santagostino E, Martinowitz U, Lissitchkov T, Pan-Petesch B, Hanabusa H, Oldenburg J, Boggio L, Negrier C, Pabinger I, von Depka Prondzinski M, Altisent C, Castaman G, Yamamoto K, Álvarez-Roman MT, Voigt C, Blackman N, Jacobs I; PROLONG-9FP Investigators Study Group. Long acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial. Blood 2016; 127: 1761–9.
25. Pasi J, Perry DJ, Mahlangu J, Konkle BA, Rangarajan S, Brown S, Hanabusa H, Jackson S, Pabinger I, Cristiano LM, Dong Y, Tsao E, Pierce GF, Allen G. Long-term safety and efficacy of rFVIIIFc in adults and adolescents with severe hemophilia A: a longitudinal analysis of A-LONG and ASPIRE. ASH Annual Meeting Abstract. Blood 2015; 126: 92–5599.
26. Mahdi AJ, Obaji SG, Collins PW. Role of enhanced half-life factor VIII and IX in the treatment of haemophilia. Br J Haematol 2015; 169: 768–76.
27. Carcao M. Changing paradigm of prophylaxis with longer acting factor concentrates. Haemophilia 2014; 20(Suppl. 4): 99–105.
28. Mahlangu J, Shapiro AD, Pasi J, Ragni MV, Ozelo MC, Oldenburg J, Matsushita T, Baker RI, Yuan H, Santiago AR, Pierce GF, Allen G, Mei B. Extended-interval prophylaxis with rFIXFc in adults and adolescents with hemophilia B: interim results of the B-YOND extension study. ASH Annual Meeting Abstract. Blood 2015; 126: 92–5599.
29. Srivastava A, Brewer AK, Mauser-Bunschoten EP, Key NS, Kitchen S, Llinas A, Ludlam CA, Mahlangu JN, Mulder K, Poon MC, Street A; Treatment guidelines working group on behalf of The World Federation Of Hemophilia. Haemophilia 2013; 19: e1–479.
30. Mahlangu JN, Ragni M, Gupta N, Rangarajan S, Klamroth R, Oldenburg J, Nogami K, Young G, Cristiano LM, Dong Y, Allen G, Pierce GF, Robinson B. Long-acting recombinant factor VIII Fc fusion protein (rFVIIIFc) for perioperative haemostatic management in severe haemophilia A. Thromb Haemost 2016; 116: 1–8.
31. Brand B, Gruppo R, Wynn TT, Griskevicius L, Fernandez MFL, Greblikas F, Dvorak T, Patrone L, Fuerlinger M, Abbuehl BE. Initial results of a clinical trial evaluating a full-length pegylated recombinant factor VIII with extended half life for the perioperative control of hemostasis in hemophilia A. Abstracts of the XXV Congress of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 2015; 13(Suppl. S2): 349.
32. Powell JS, Apte S, Chambost H, Hermans C, Jackson S, Josephson NC, Mahlangu JN, Ozelo MC, Peerlinck K, Pasi J, Perry D, Ragni MV, Wang X, Jiang H, Li S, Cristiano LM, Innes A, Nugent K, Brennan A, Luk A, et al. Long-acting recombinant factor IX Fc fusion protein (rFIXFc) for perioperative management of subjects with haemophilia B in the phase 3 B-LONG study. Br J Haematol 2015; 168: 124–34.
33. Ragni MV, Pasi KJ, White GC, Giangrande PL, Courter SG, Tubridy KL. Use of recombinant factor IX in subjects with haemophilia B undergoing surgery. Haemophilia 2002; 8: 91–7.
34. Quon DV, Logan L. Safety and efficacy of plasma-derived coagulation factor IX concentrate (AlphaNine(R) SD) in patients with haemophilia B undergoing surgical intervention: a single institution retrospective analysis. Haemophilia 2002; 17: e196–201.
35. Collins PW, Møss J, Knobe K, Groth A, Colberg T, Watson E. Population pharmacokinetic modeling for dose setting of nonacog beta pegol (N9-GP), a glycoPEGylated recombinant factor IX. J Thromb Haemost 2012; 10: 2305–12.
36. Escobar M, Sallah S. Hemophilia A and B: focus on arthropathy and variables affecting bleeding severity and prophylaxis. J Thromb Haemost 2013; 11: 1449–53.
37. Negrier C, Lepatan LM, Lubetsky A, Karim FA, Pan-Petesch B, Tagliaferri A, Altisent C, Curtin J, Male C, Lienhart A, Wolko D, Voigt C, Jacobs I, Santagostino E. Efficacy and safety of recombinant fusion protein linking coagulation factor IX with albumin (RIX-FP) in previously treated patients with hemophilia B undergoing a surgical procedure. Abstracts of the XXV Congress of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 2015; 13(Suppl. 2): 843.
38. Weimer T, Wormsbacher W, Kronthaler U, Lang W, Liebing U, Schulte S. Prolonged in-vivo half-life of factor VIIa by fusion to albumin. Thromb Haemost 2008; 99: 659–67.
39. Fares F, Guy R, Bar-Ilan A, Felikman Y, Fima E. Designing a long-acting human growth hormone (hGH) by fusing the carboxyl-terminal peptide of human chorionic gonadotropin beta-subunit to the coding sequence of hGH. Endocrinology 2010; 151: 4410–17.
40. Hart G, Ilan AB, Hershkovitz O, Binder L, Zakar M, Fima E. CTP, an effective, safe technology with a strong clinical precedence for the generation of a long-acting factor FVIIa, demonstrating superior pharmacokinetics, pharmacodynamics and hemostatic effect following IV administration in animal models. Abstracts of the 7th Annual Congress of the European Association for Haemophilia and Allied Disorders. Hemophilia 2014; 20(Suppl. s2): 36.
41. Salas J, Liu T, Lu Q, Kulman JD, Ashworth T, Kistanova E, Moore N, Pierce GF, Jiang H, Peters R. Enhanced pharmacokinetics of factor VIIa as a monomeric Fc fusion. Thromb Res 2015; 135: 970–6.
42. Hilden I, Lauritzen B, Sorensen BB, Clausen JT, Jespersgaard C, Krogh BO, Bowler AN, Breinholt J, Gruhler A, Svensson LA, Petersen HH, Petersen LC, Balling KW, Hansen L, Hermit MB, Egebjerg T, Friederichsen B, Ezban M, Bjørn SE. Hemostatic effect of a monoclonal antibody mAb 2021 blocking the interaction between FXa and TFPI in a rabbit hemophilia model. Blood 2012; 119: 5871–8.
43. Chowdary P, Lethagen S, Friedrich U, Brand B, Hay C, Abdul Karim F, Klamroth R, Knoebl P, Laffan M, Mahlangu J, Miesbach W, Dalsgaard Nielsen J, Martín-Salces M, Angchaisuksiri P. Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial. J Thromb Haemost 2015; 13: 743–54.
44. Bennet CF, Swayzea EE. RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu Rev Pharmacol Toxicol 2010; 50: 259–93.
45. Pasi JK, Georgiev P, Mant T, Creagh MD, Lissitchkov T, Bevant D, Austin S, Hay CR, Kazmi R, Chowdary P, Ragni MV, Chen J, Akin A, Sorensen B, Rangarajan S. A subcutaneously administered investigational RNAi therapeutic (ALN-AT3) targeting antithrombin for treatment of hemophilia: interim weekly and monthly dosing results in patients with hemophilia A and B. ASH Annual Meeting Abstract. Blood 2015; 126: 92–5599.
46. Kitazawa T, Igawa T, Sampei Z, Muto A, Kojima T, Soeda T, Yoshihashi K, Okuyama-Nishida Y, Saito H, Tsunoda H, Suzuki T, Adachi H, Miyazaki T, Ishii S, Kamata-Sakurai M, Iida T, Harada A, Esaki K, Funaki M, Moriyama C, et al. A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model. Nat Med 2012; 18: 1570–4.
47. Uchida N, Sambe T, Yoneyama K, Fukazawa N, Kawanishi T, Kobayashi S, Shima M. A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects. Blood 2016; 127: 1633–41.
48. Shima M, Hanabusa H, Taki M, Matsushita T, Sato T, Fukutake K, Fukazawa N, Yoneyama K, Yoshida H, Nogami K. Factor VIII-mimetic function of humanized bispecific antibody in hemophilia A. N Engl J Med 2016; 374: 2044–53.
49. Hantgan RR, Hindriks G, Taylor RG, Sixma JJ, de Groot PG. Glycoprotein Ib, von Willebrand factor, and glycoprotein IIb:IIIa are all involved in platelet adhesion to fibrin in flowing whole blood. Blood 1990; 76: 345–53.
50. Sadler JE, Budde U, Eikenboom JC, Favaloro EJ, Hill FG, Holmberg L, Ingerslev J, Lee CA, Lillicrap D, Mannucci PM, Mazurier C, Meyer D, Nichols WL, Nishino M, Peake IR, Rodeghiero F, Schneppenheim R, Ruggeri ZM, Srivastava A, Montgomery RR, et al. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost 2006; 4: 2103–14.
51. Hampshire DJ, Goodeve AC. The International Society on Thrombosis and Haematosis von Willebrand disease database: an update. Semin Thromb Hemost 2011; 37: 470–9.
52. Eikenboom J, Van Marion V, Putter H, Goodeve A, Rodeghiero F, Castaman G, Federici AB, Batlle J, Meyer D, Mazurier C, Goudemand J, Schneppenheim R, Budde U, Ingerslev J, Vorlova Z, Habart D, Holmberg L, Lethagen S, Pasi J, Hill F, Peake I Linkage analysis in families diagnosed with type 1 von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 VWD. J Thromb Haemost 2006; 4: 774–82.
53. Federici AB, Mazurier C, Berntorp E, Lee CA, Scharrer I, Goudemand J, Lethagen S, Nitu I, Ludwig G, Hilbert L, Mannucci PM. Biologic response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease: results of a multicenter European study. Blood 2004; 103: 2032–8.
54. Castaman G, Goodeve A, Eikenboom J; European Group on von Willebrand Disease. Principles of care for the diagnosis and treatment of von Willebrand disease (EUVWD). Haematologica 2013; 98: 667–74.
55. Fischer BE. Recombinant von Willebrand factor: potential therapeutic use. J Thromb Thrombolysis 1999; 8: 197–205.
56. Turecek PL, Mitterer A, Matthiessen HP, Gritsch H, Varadi K, Siekmann J, Schnecker K, Plaimauer B, Kaliwoda M, Purtscher M, Woehrer W, Mundt W, Muchitsch EM, Suiter T, Ewenstein B, Ehrlich HJ, Schwarz HP. Development of a plasma- and albumin-free recombinant von Willebrand factor. Hamostaseologie 2009; 29(Suppl. 1): S32–8.
57. Mannucci PM, Kempton C, Millar C, Romond E, Shapiro A, Birschmann I, Ragni MV, Gill JC, Yee TT, Klamroth R, Wong WY, Chapman M, Engl W, Turecek PL, Suiter TM, Ewenstein BM; rVWF Ad Hoc Study Group. Pharmacokinetics and safety of a novel recombinant human von Willebrand factor manufactured with a plasma-free method: a prospective clinical trial. Blood 2013; 122: 648–57.
58. Gill JC, Castaman G, Windyga J, Kouides P, Ragni M, Leebeek FW, Obermann-Slupetzky O, Chapman M, Fritsch S, Pavlova BG, Presch I, Ewenstein B. Hemostatic efficacy, safety, and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand disease. Blood 2015; 126: 2038–46.
59. Halimeh S, Krumpel A, Rott H, Bogdanova N, Budde U, Manner D, Faeser B, Mesters R, Nowak-Gottl U. Long-term secondary prophylaxis in children, adolescents and young adults with Von Willebrand disease. Thromb Haemost 2011; 104: 984–9.
60. Abshire TC, Federici AB, Alvarex MT, Bowen J, Carcao MD, Cox-Gill J, Key NS, Kouides PA, Kurnik K, Lail AE, Leebeek FWG, Makris M, Mannucci PM, Winikoff R, Berntorp E. Prophylaxis in severe forms of Von Willebrand's disease: results from the Von Willebrand Disease Prophylaxis Network (VWD PN). Haemophilia 2013; 19: 76–81.
61. Abshire T, Cox-Gill J, Kempton CL, Leebeek FWG, Carcao M, Kouides P, Donfield S, Berntorp E. Prophylaxis escalation in severe von Willebrand disease: a prospective study from the Von Willebrand Disease Prophylaxis Network. J Thromb Haemost 2015; 13: 1585–9.
62. Jilma B, Paulinska P, Jilma-Stohlawetz P, Gilbert JC, Hutabarat R, Knöbl P. A randomised pilot trial of the anti-von Willebrand factor aptamer ARC1779 in patients with type 2b von Willebrand disease. Thromb Haemost 2010; 104: 563–70.
63. Jilma-Stohlawetz P, Knöbl P, Gilbert JC, Jilma B. The anti-von Willebrand factor aptamer ARC1779 increases von Willebrand factor levels and platelet counts in patients with type 2B von Willebrand disease. Thromb Haemost 2012; 108: 284–90.
64. Peyvandi F, Di Michele D, Bolton-Maggs PHB, Lee CA, Tripodi A, Srivastava A, for the project on consensus definitions in rare bleeding disorders of the factor VIII/factor IX Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. Classification of rare bleeding disorders (RBDs) based on the association between coagulant factor activity and clinical bleeding severity. J Thromb Haemost 2012; 10: 1938–43.
65. Mumford AD, Ackroyd S, Alikhan R, Bowles L, Chowdary P, Grainger J, Mainwaring J, Mathias M, O'Connell N; BCSH Committee. Guideline for the diagnosis and management of the rare coagulation disorders: a United Kingdom Haemophilia Centre Doctors’ Organization guideline on behalf of the British Committee for Standards in Haematology. Br J Haematol 2014; 167: 304–26.
66. Karimi M, Vafafar A, Haghpanah S, Payandeh M, Eshghi P, Hoofar H, Afrasiabi A, Gerdabi J, Ardeshiri R, Menegatti M, Peyvandi F. Efficacy of prophylaxis and genotype–phenotype correlation in patients with severe factor X deficiency in Iran. Haemophilia 2012; 18: 211–15.
67. Austin SK, Brindley C, Kavakli K, Norton M, Shapiro A; FX Investigators Group. Pharmacokinetics of a high-purity plasma-derived factor X concentrate in subjects with moderate or severe hereditary factor X deficiency. Haemophilia 2016; 22: 426–32.
68. Lawrie A, Berbenni C, Nardini I, Mackie I, Machin S, Peyvandi F. In vitro characterizations of the first therapeutic factor V concentrate, in development. J Thromb Haemost 2014; 12(Suppl. 1): 38–9.
69. Keeling D, Tait C, Makris M. Guideline on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders. A United Kingdom Haemophilia Center Doctors’ Organisation (UKHCDO) guideline approved by the British Committee for Standards in Haematology. Haemophilia 2008; 14: 671–84.
70. Lancellotti S, Basso M, De Cristofaro R. Congenital prothrombin deficiency: an update. Semin Thromb Hemost 2013; 39: 596–606.
71. Ortel TL. Clinical and laboratory manifestations of anti-factor V antibodies. J Lab Clin Med 1999; 133: 326–34.
72. Nicolaisen EM, Hansen LL, Poulsen F, Glazer S, Hedner U. Immunological aspects of recombinant factor VIIa (rFVIIa) in clinical use. Thromb Haemost 1996; 76: 200–4.
73. Salomon O, Zivelin A, Livnat T, Seligsohn U. Inhibitors to factor XI in patients with severe factor XI deficiency. Semin Hematol 2006; 43(Suppl. 1): S10–12.
74. Lorand L, Velasco PT, Rinne JR, Amare M, Miller LK, Zucker ML. Autoimmune antibody (IgG Kansas) against the fibrin stabilizing factor (factor XIII) system. Proc Natl Acad Sci USA 1988; 85: 232–6.
75. Soucie JM, McAlister S, McClellan A, Oakley M, Su Y. The universal data collection surveillance system for rare bleeding disorders. Am J Prev Med 2010; 38: S475–81.
76. Makris M, Calizzani G, Fischer K, Gilman EA, Hay CR, Lassila R, Lambert T, Ludlam CA, Mannucci PM. EUHASS: The European Haemophilia Safety Surveillance system. Thromb Res 2011; 127: S22–5.
77. Sehgal A, Qian K, Hettinger J, Sorensen B, Akinc A. Antithrombin reduction improves coagulation in rare bleeding disorder plasma. Abstracts of the XXV Congress of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 2015; 13(Suppl. S2): 162.